|
|
Article: Altus Pharmaceuticals Reports Dosing First Patient in a Phase 2 Trial of ALTU-238 for Pediatric Growth Hormone Deficiency.
- Article from:
- Business Wire
- Article date:
- June 10, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- - Company's Vice President of Clinical Development To Present at The Endocrine Society's 91st Annual Meeting - -
WALTHAM, Mass. -- Altus Pharmaceuticals Inc. (NASDAQ: ALTU) today announced that patient dosing in its Phase 2 trial for ALTU-238 in growth hormone deficiency pediatric subjects began on June 2, 2009. ALTU-238 is a long-acting, extended-release formulation of recombinant human growth hormone (rhGH, somatropin), which is being developed utilizing Altus' proprietary protein crystallization technology. ALTU-238 is a ready-to-use liquid suspension of crystallized rhGH that preserves the structure of the rhGH molecule without the need for pegylation, ...